Welcome to this week’s edition of Weekend Wonderings. I expect to see a good many ‘May flowers’ in western NY, since we’re getting quite a bit of ‘April showers’. Grab whatever beverage that you need and let’s proceed. Go ahead, I’ll wait…
We have a couple of things today. First up is a clever, to me, “cross-use” of an old technique to help address another issue. Remember/familiar with nicotine patches as a tool to wean smokers off cigarettes? Here’s a tweak to the idea to use the patch as a cancer drug delivery system.
“.. investigators at (OSUCCC – James) hope soon to begin clinical testing of an adhesive medicated patch that releases an anticancer drug called fenretinide directly into precancerous oral lesions to help prevent malignancy. The patch is designed to hold the medication in place so that none of it spreads to the rest of the body, diminishing potential side effects.”
The article is a short, interesting read; it is a great example that even if you have a drug that has efficacy against a disease, you still need to deliver it efficiently to take advantage of its properties.
Moving along, I hope that you don’t need this, but here is a link to Clinical Trials at OSUCCC. It may be a good idea to bookmark this link, just in case..
Welcome to this week’s edition of Weekend Wonderings. Basketball season is over, if you’re an Ohio State fan. And probably if you’ve gotten into any NCAA pools, as well. The Spring sports are well under way, and we have some time before OSU’s Spring Game. Grab whatever beverage that you need and let’s proceed.
An Overview of the BR-002 Trial in Breast Cancer:
Julia White, MD, professor, director, Breast Radiation Oncology, vice chair, Clinical Research, The Ohio State University Comprehensive Cancer Center, discusses the BR-002 trial, which will evaluate the rate of complete tumor ablation of breast cancers that are less than or equal to 2 centimeters.
Ablation refers to local methods that destroy the tumor without removing it. Ablation treatment of tumors does work. They do a tremendous job of it at The James.
If you want to keep current with cancer research and treatment at The James, you can sign up to their blog.
Welcome to another edition of Weekend Wonderings. Take a minute, grab whatever you drink on a Sunday afternoon and let’s carry on.
Go ahead, I’ll wait.
First, by the end of the month, the James will open a Phase 2 clinical trial to test two drugs for the treatment of triple negative breast cancer – a very aggressive type of cancer with high rates of recurrence.
Triple negative breast cancer, which accounts for 15 to 20 percent of breast cancers, is so hard to treat because it doesn’t have any of the receptors (substances found inside cells that give rise to cancer) that existing drugs are able to fight…
Let’s hope that these trials come up with a solution, because if treatment drugs can’t “find” anything to latch onto, the treatment just becomes that more difficult.
Next, is an article written by Sameek Roychowdhury. MD, PhD about the use of genomics in clinical trials.
Gene sequencing technology called next-generation sequencing will enable oncologists to determine which of 200-plus significant genes are altered in a patient’s cancer and to use this information to guide therapy. Ohio State is among the leaders in the country in promoting and championing this precision oncology strategy.
I’m a believer in the use of genomics as both a diagnostic and a treatment approach . There are many “families” of cancer, such as breast, prostate, lung, etc., and several subsets within each family. This is not a one-size-fits-all disease. I’m very familiar with the subsets where there is no definitive cause; which leads to the disease likely being incurable. This genomics approach may get us over that hurdle. Read More